HomeComparePHAS vs YUM

PHAS vs YUM: Dividend Comparison 2026

PHAS yields 2853.07% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHAS wins by $281872346866.93M in total portfolio value
10 years
PHAS
PHAS
● Live price
2853.07%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$281872346867.04M
Annual income
$263,691,193,706,389,300.00
Full PHAS calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — PHAS vs YUM

📍 PHAS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHASYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHAS + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PHAS pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHAS
Annual income on $10K today (after 15% tax)
$242,510.70/yr
After 10yr DRIP, annual income (after tax)
$224,137,514,650,430,900.00/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, PHAS beats the other by $224,137,514,650,396,540.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHAS + YUM for your $10,000?

PHAS: 50%YUM: 50%
100% YUM50/50100% PHAS
Portfolio after 10yr
$140936173433.57M
Annual income
$131,845,596,853,214,880.00/yr
Blended yield
93.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

PHAS
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHAS buys
0
YUM buys
0
No recent congressional trades found for PHAS or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHASYUM
Forward yield2853.07%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$281872346867.04M$107.9K
Annual income after 10y$263,691,193,706,389,300.00$40,443.52
Total dividends collected$280611873155.80M$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: PHAS vs YUM ($10,000, DRIP)

YearPHAS PortfolioPHAS Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$296,007$285,306.70$10,982$282.06+$285.0KPHAS
2$8,209,503$7,892,775.47$12,189$438.29+$8.20MPHAS
3$213,363,270$204,579,102.60$13,731$688.32+$213.35MPHAS
4$5,197,428,076$4,969,129,376.72$15,789$1,097.12+$5197.41MPHAS
5$118,688,009,645$113,126,761,603.35$18,679$1,785.08+$118687.99MPHAS
6$2,541,344,545,416$2,414,348,375,096.37$22,975$2,988.18+$2541344.52MPHAS
7$51,033,223,710,004$48,313,985,046,408.66$29,784$5,200.49+$51033223.68MPHAS
8$961,336,701,807,468$906,731,152,437,763.20$41,408$9,539.16+$961336701.77MPHAS
9$16,991,731,925,840,448$15,963,101,654,906,456.00$63,071$18,765.27+$16991731925.78MPHAS
10$281,872,346,867,038,600$263,691,193,706,389,300.00$107,930$40,443.52+$281872346866.93MPHAS

PHAS vs YUM: Complete Analysis 2026

PHASStock

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full PHAS Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this PHAS vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHAS vs SCHDPHAS vs JEPIPHAS vs OPHAS vs KOPHAS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.